Table 3.

Percentage change in absolute lymphocyte count (ALC) by prior natalizumab (NAT) exposure.

	Patients with prior NAT exposure		Patients without prior NAT exposure
	Mean,×109/la(n = 132)b	Mean % change from baselinec	Mean,×109/la(n = 344)	Mean % change from baselinec
Baseline	2.90		1.97
Month 6	1.41 (1.34–1.48)	–51.3	1.34 (1.29–1.39)	–32.1
Month 12	1.21 (1.13–1.29)	–58.2	1.25 (1.19–1.31)	–36.4
Month 15	1.15 (1.07–1.23)	–60.4	1.22 (1.16–1.29)	–37.8

^aValues in parentheses represent mean 95% confidence intervals.

^bUp to 180 days prior to dimethyl fumarate (DMF), 132 patients received NAT (two patients received NAT >180 days prior to DMF and were excluded from the analysis).

^cMean values at months 6, 12, and 15 were estimated using a repeated-measures mixed-effects model with baseline ALC, time (log-transformed), and baseline ALC×time interaction effect. Time (log-transformed) was a random effect. Percentage change was estimated from baseline and the estimated mean change.